<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C, Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee and BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. London (England): British Society for Rheumatology; 2010. 23 p.  [206 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837498&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-&amp;alpha; blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44: 157-63.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Rheumatoid arthritis  (714.0)"/><FieldValue Value="MSH: Antibiotic Prophylaxis ; Antirheumatic Agents ; Antitubercular Agents ; Arthritis, Rheumatoid ; Bacterial Infections ; Blood Cell Count ; Chickenpox Vaccine ; Comorbidity ; Contraception ; Counseling ; Hepatitis B Vaccines ; Influenza Vaccines ; Medication Therapy Management ; Patient Safety ; Perioperative Care ; Pneumococcal Vaccines ; Referral and Consultation ; Risk Assessment ; Risk Factors ; Virus Diseases "/><FieldValue Value="MTH: Antibiotic Prophylaxis ; Antirheumatic Agents ; Bacterial Infections ; blood cell count ; Chickenpox Vaccine ; Contraceptive methods ; Counseling ; Hepatitis B Vaccines ; Influenza virus vaccine ; patient safety ; Pneumococcal vaccine ; Rheumatoid Arthritis ; Risk Assessment ; risk factors ; Virus Diseases "/><FieldValue Value="SNOMEDCT_US: Anti-rheumatic agent  (372888006); Anti-rheumatic agent  (88279005); Anti-tumor necrosis factor alpha drug  (416897008); Anti-tumor necrosis factor alpha drug  (420693002); Antibiotic prophylaxis  (422181004); Antituberculosis agent  (2537003); Antituberculosis agent  (324453004); Bacterial infection by site  (301811001); Bacterial infection by site  (87628006); Blood cell count  (88308000); Contraception  (13197004); Counseling  (129441002); Counseling  (409063005); Infection surveillance  (170502008); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Perioperative care  (133897009); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Rheumatoid arthritis  (69896004); Risk assessment  (225338004); Risk factor  (80943009); Varicella virus vaccine  (108729007); Varicella virus vaccine  (396442000); Viral disease  (34014006)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Rheumatoid arthritis&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: These guidelines do not cover other inflammatory arthropathies or diseases.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Rheumatology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To produce recommendations on the safety aspects and the appropriate use of anti-tumour necrosis factor (anti-TNF) drugs in rheumatoid arthritis (RA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To review other available guidelines (previous British Society for Rheumatology [BSR], European League Against Rheumatology, American College of Rheumatology, and other international guidelines), and endorse these where appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide a best-practice approach to the evidence-based use of anti-TNF therapies in RA that were most relevant to patients and health-care professionals in clinical practice in the United Kingdom (UK) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult patients in the United Kingdom with rheumatoid arthritis&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessing patients for infection before and during anti-tumour necrosis factor (anti-TNF) therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient counselling on risk:benefit of anti-TNF therapy, including risk of malignancy, and food hygiene &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment, screening (as indicated) and treatment surveillance for mycobacterial, bacterial and viral infection, including hepatitis, HIV and tuberculosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treating mycobacterial infection before initiation of anti-TNF therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prophylactic anti-tuberculosis treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate monitoring of changes in comorbid conditions and concomitant treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to specialist care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of peri-operative anti-TNF therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of immunizations (influenza, pneumococcal, varicella, hepatitis B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discontinuation or change of treatment for malignancy, autoimmune disease, demyelination disorder, cardiac failure/ischaemic heart disease, interstitial lung disease, psoriasis, or uveitis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Regular monitoring of blood counts &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pregnancy prevention while patient or partner is on anti-TNF therapy (breastfeeding to be decided on an individual basis) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Incidence of serious infection in patients on anti-tumour necrosis factor (anti-TNF) therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of food-borne infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of new or worsening malignancy, autoimmune disease, demyelination disorders, cardiac failure/ischaemic heart disease, haematological complications, interstitial lung disease, psoriasis, or uveitis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incidence of peri-operative infection in patients on anti-TNF therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fetal complications, morbidity, and mortality during pregnancy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and costs for screening tests for tuberculosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Safety and patient tolerance of anti-TNF treatments in patients with hepatitis B, hepatitis C, human immunodeficiency virus, or demyelination disorders &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness and patient tolerance of immunizations during anti-TNF therapy , e.g., influenza, pneumococcal, and hepatitis B &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duration of immunization responses in patients on anti-TNF therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rate of resolution of symptoms of autoimmune disease or demyelination disorders after withdrawal of anti-TNF therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Comprehensive literature searches were performed using relevant search terms to seek evidence to determine what changes to the previous British Society for Rheumatology (BSR) safety guidelines were required. Searches were conducted using primarily MEDLINE and PubMed. A manual search from the references cited by generated articles was also used. All searches were performed for literature up to October 2009. Abstracts were read for relevant evidence from the BSR, the European League Against Rheumatology and American College of Rheumatology annual conferences up to October 2009.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;4%&quot; valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Ia&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analysis of randomised controlled trials (RCTs)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Ib&lt;/th&gt;&#xD;&#xA;            &lt;td&gt;At least one RCT&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IIa&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one well-designed controlled study, but without randomisation&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IIb&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one well-designed quasi-experimental design&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one non-experimental descriptive study (e.g., comparative, correlation, or case study)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IV&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert committee reports, opinions, and/or experience of respected authorities&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Evidence was graded according to the strength of literature to support each statement, using the grading suggested by the Royal College of Physicians of London (National Clinical Guidelines for Stroke by the Intercollegiate Stroke Working Party, June 2004).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The document was prepared in accordance with the principles outlined in the &lt;a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Trust Web site&quot;&gt;Appraisal of Guidelines Research and Evaluation (AGREE) guidelines&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The scope for the guidelines was agreed by the British Society of Rheumatologists (BSR) Rheumatoid Arthritis (RA) Biologics Guidelines Group (BSRBG) in 2007, with a view to producing recommendations on the safety aspects and the appropriate use of anti-tumour necrosis factor (anti-TNF) drugs in RA. As a principle, the group also agreed to review other available guidelines (previous BSR, the European League Against Rheumatism [EULAR], American College of Rheumatology (ACR) and other international guidelines), and endorse these where appropriate. The group was mindful of the need not to reproduce the considerable work of other evidence-based guidelines, and to concentrate on those areas that were most relevant to patients and health-care professionals in clinical practice in the United Kingdom (UK).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The National Rheumatoid Arthritis Society provided patient representation on the BSRBG.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analysis of randomised controlled trials (RCTs) &lt;em&gt;or&lt;/em&gt; at least one RCT&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed controlled study but without randomisation &lt;em&gt;or&lt;/em&gt; well-designed quasi-experimental study &lt;em&gt;or&lt;/em&gt; well-designed descriptive study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert committee reports, opinions, &lt;em&gt;and/or&lt;/em&gt; experience of respected authorities&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The cost of Quantiferon (&amp;pound;35/test) and T-spot (&amp;pound;100/test) screening of all United Kingdom (UK) patients prior to treatment with anti-tumour necrosis factor (anti-TNF) would prove prohibitive. At the age of 50 years the annual incidence of active tuberculosis (TB) disease in the UK White Caucasian population is approximately 5/100,000 and the incidence of latent TB is approximately 10 times this level (50/100,000). Therefore, the number of tests needed to detect one case of latent infection would be 2,000, at a cost of &amp;pound;70,000 with Quantiferon and &amp;pound;200,000 with the T-spot test. The economics improve slightly in older patients but are much worse (more than double the cost) for patients under the age of 35 years. The cost-effectiveness is better for patients from ethnic minorities known to be at higher risk of TB. For patients from South Asia, the incidence of TB is 120/100 000 and in black Africans it is 240/100 000, and this reduces the numbers needed to test to detect one positive case to 82 and 41, respectively. The true-negative predictive value of a negative test or the true-positive predictive value of a positive test is still not known, however, and these tests are currently therefore not recommended by the British Thoracic Society as TB-screening tools. National Institute for Health and Clinical Excellence (NICE) are currently developing guidelines on the use of these interferon-gamma (IFN-gamma) tests for diagnosing latent TB with a planned publication date of November 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Final drafts of the guidelines have been circulated to patient representative bodies for comment, and feedback has been incorporated where appropriate. Drafts of the guidelines were also circulated at the British Society for Rheumatology (BSR) Annual General Meeting in Glasgow in April 2009, and feedback considered, and incorporated where appropriate.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence (&lt;strong&gt;I-IV&lt;/strong&gt;) supporting the recommendations and ratings of recommendations (&lt;strong&gt;A-C&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Infection&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Infection in General&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 1: Anti-tumour necrosis factor (anti-TNF) therapy should not be initiated in the presence of serious active infections. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 2: Anti-TNF therapy should be discontinued in the presence of serious infections, but can be recommenced once the infection has resolved clinically. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 3: Use anti-TNF therapy with caution after discussing the relative risks (RRs) and benefits in the following circumstances:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Chronic infected leg ulcers &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Septic arthritis of a native joint within the last 12 months &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sepsis of a prosthetic joint within the last 12 months, or indefinitely if the joint remains &lt;em&gt;in situ&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Persistent or recurrent chest infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Indwelling urinary catheter &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bronchiectasis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypogammaglobulinaemia &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;(&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Mycobacterial Infections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 4: Prior to commencing treatment with anti-TNF therapy, all patients should be screened for mycobacterial infection in accordance with the latest National guidelines. Active mycobacterial infection needs to be adequately treated before anti-TNF therapy can be started. (&lt;strong&gt;Level IIb evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 5: Prior to commencing anti-TNF therapy, consideration of prophylactic anti-tuberculosis (TB) therapy (as directed by the latest National guidelines) should be given to patients with evidence of potential latent disease (past history of TB or abnormal chest X-ray). (&lt;strong&gt;Level IIb evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 6: All patients commenced on anti-TNF therapies should be closely monitored for mycobacterial infections. This should continue for at least 6 months after stopping treatment due to the prolonged elimination phase of the drug. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 7: Patients on anti-TNF therapy who develop symptoms suggestive of mycobacterial infections should receive full anti-mycobacterial chemotherapy, but may continue with their anti-TNF therapy if clinically indicated. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Other Opportunistic Bacterial and Fungal Infections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 8: Patients on anti-TNF should be informed of appropriate food hygiene (see Arthritis Research UK patient information leaflets on etanercept (&quot;Etanercept,&quot; 2011), infliximab (&quot;Infliximab,&quot; 2011), and adalimumab (&quot;Adalimumab,&quot; 2011). (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 9: Health-care professionals managing patients on anti-TNF therapy should be aware of the risk of opportunistic infections in patients on anti-TNF therapy. They should have a high index of suspicion for atypical and opportunistic infections, and anti-TNF therapy should be promptly stopped in suspected cases and patients should have rapid access to specialist health care for consideration of early anti-bacterial/anti-fungal treatment. (&lt;strong&gt;Level IIII evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Varicella Infections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 10: If a patient on anti-TNF treatment, or one of their household contacts, develops primary varicella (chickenpox), and if the risks from infection are perceived to be significant, the patient should be considered for varicella zoster immune globulin (VZIG). Shingles should be treated conventionally. (&lt;strong&gt;Level IIb evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hepatitis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Hepatitis B Virus (HBV)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 11: Screening for risk factors for HBV infection should be performed prior to commencing anti-TNF therapy and HBV tests should be performed in patients with risk factors. In patients who are HBV positive, a risk:benefit assessment should be undertaken, as anti-TNF treatment may be safe if appropriate anti-viral treatment is given. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 12: Close monitoring of serum aminotransaminases and HBV deoxyribonucleic acid (DNA) load during therapy should be considered in patients with HBV treated with anti-TNF therapy and concomitant anti-viral treatment would be recommended. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 13: Patients with serological evidence of cleared past infection (hepatitis B surface antigen negative/core antibody [anti-HBcAb] positive) should have their HBV serology monitored during therapy and may require concomitant anti-viral treatment if detrimental changes develop. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Hepatitis C Virus (HCV)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 14: Screening for risk factors for HCV infection should be performed prior to commencing anti-TNF and HCV tests should be performed in patients with risk factors. Although studies to date suggest that anti-TNF therapies do not have a detrimental effect on HCV infection, anti-TNF should continue to be used with caution in such patients. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 15: Close monitoring of serum aminotransaminases and HCV RNA during therapy should be performed in patients with HCV treated with anti-TNF therapy. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Human Immunodeficiency Virus (HIV)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 16: Risk factors for HIV infection should be documented prior to commencing anti-TNF therapy and, if present, an HIV test should be done. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 17: In considering anti-TNF use in HIV-positive patients, the following should influence decision-making, that a reasonable benefit to risk ratio exists for HIV patients if: (i) HIV infection is controlled and patients are not severely immunosuppressed (e.g., CD4 count &amp;gt;200 and HIV viral load &amp;lt;60,000 copies per mm&lt;sup&gt;3&lt;/sup&gt;); (ii) anti-TNF therapy is given in combination with highly active anti-retroviral therapy (HAART); and (iii) close monitoring of viral load and CD4 count is undertaken after anti-TNF therapy is started, and treatment changes are made in light of these results. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Peri-operative Infection&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 18: In rheumatoid arthritis (RA) patients on anti-TNF therapies, the potential benefit of preventing post-operative infections by stopping treatment (different surgical procedures pose different risks of infection and wound healing) should be balanced against the risk of a peri-operative flare in RA activity. (&lt;strong&gt;Level IIa evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 19: If anti-TNF treatment is to be stopped prior to surgery, consideration should be given to stopping at a time three to five times the half-life for the relevant drug before surgery (infliximab 8-9.5 days, etanercept 100 h, adalimumab 15-19 days). (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 20: Anti-TNF should not be restarted after surgery until there is good wound healing and no evidence of infection. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Immunization&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 21: When considering primary immunizations and live attenuated immunizations in patients on anti-TNF therapy, it should be acknowledged that data on the effects of anti-TNF therapies are limited. Until further evidence is available, the British Society for Rheumatology (BSR) recommendations on the use of immunizations in patients on immunosuppressive therapy should be adhered to in patients on anti-TNF therapy (British Society for Rheumatology, 2002). (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 22: Although there may be an attenuated response (particularly if methotrexate [MTX] is being co-prescribed), patients on anti-TNF therapy should receive both influenza (including vaccines generated for specific flu outbreaks such as the recent swine flu) and pneumococcal immunizations unless there are contraindications. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 23: Prior to commencing anti-TNF therapy, hepatitis B immunization should be considered for at-risk patients. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Malignancy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 24: Patients commencing anti-TNF therapy should be informed that overall there is no conclusive evidence for an increase in risk of solid tumours or lymphoproliferative disease with the anti-TNF therapies above that which would be expected for the rest of the RA population, but ongoing vigilance is required. (&lt;strong&gt;Level Ia evidence, Grade of recommendation A&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 25: Patients should be investigated for potential malignancy if clinically suspected, and anti-TNF treatment should be stopped if malignancy is confirmed. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 26: Caution should be exercised in the use of anti-TNF therapies in patients with previous malignancy. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 27: The effect of anti-TNF therapies on pre-malignant conditions such as Barrett's oesophagus, cervical dysplasia and large bowel polyps is unknown. Caution should be exercised in the use of anti-TNF therapies in such patients. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 28: Patients should be advised that there appears to be an increased risk of some skin cancers with anti-TNF therapy and on preventative skin care and skin surveillance. Patients should be encouraged to promptly report any new persistent skin lesions. (&lt;strong&gt;Level IIb evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Autoimmune Diseases&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 29: If a lupus-like syndrome or other significant autoimmune disease develops while on anti-TNF therapies, treatment should be discontinued and appropriate interventions should be initiated. Re-challenging with anti-TNF therapy should only be undertaken with caution. (&lt;strong&gt;Level III evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Demyelination&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 30: Anti-TNF therapy should not be given when there is a clear history of multiple sclerosis and should be used with caution with other demyelinating diseases. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 31: Anti-TNF therapy should be withdrawn if demyelination occurs and the patient should be referred for specialist investigation. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cardiac Failure and Ischaemic Heart Disease&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 32: Anti-TNF therapy should not be initiated in patients with New York Heart Association (NYHA) Grade 3 or 4 cardiac failure (see Table 2 in the original guideline document) and should be used with caution in patients with mild (NYHA Grade 1 or 2) cardiac failure. (&lt;strong&gt;Level Ib evidence, Grade of recommendation A&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 33: Anti-TNF therapy should be discontinued if cardiac failure develops or worsens while on treatment. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Haematological Complications&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 34: For all patients on anti-TNF therapy including those not on concomitant disease-modifying anti-rheumatic drugs (DMARDs), full blood counts should be monitored regularly. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pregnancy and Lactation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The safety of the anti-TNF therapies has not been established through pregnancy or lactation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 35: Precautions against pregnancy should be exercised in both female and male patients treated with anti-TNF (or their partners). Continuation of anti-TNF therapy could be considered in patients wishing to conceive/father a child if the risks of stopping treatment are perceived to be high.*&lt;sup&gt; &lt;/sup&gt;(&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 36: Consideration should be given to stopping anti-TNF in a woman who becomes pregnant on treatment but continuation of anti-TNF therapy could be considered if the risks of stopping treatment are perceived to be high. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 37: The pros and cons of breastfeeding in patients treated with anti-TNF therapies should be considered on an individual basis. (&lt;strong&gt;Level IV evidence, Grade of recommendation C&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Current data sheet recommendations are that infliximab should be discontinued for 6 months and that adalimumab should be discontinued for 5 months before a female patient becomes pregnant. No specific data sheet guidance is currently available on the duration that female patients should be off etanercept prior to becoming pregnant or on male patients treated with any of the anti-TNF agents who wish to father a child.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Interstitial Lung Disease&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 38: Patients with pre-existing interstitial lung disease (ILD) should have monitoring of their lung function if treated with anti-TNF therapies, and consideration should be given to stopping anti-TNF therapy in patients with worsening, or new features of ILD. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Psoriasis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 39: If psoriasis develops on anti-TNF therapy patients should receive conventional psoriasis treatment and consideration should be given to stopping anti-TNF therapy if the skin lesions persist despite specialist dermatology treatment and advice or are particularly severe. (&lt;strong&gt;Level III evidence, Grade of Recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Uveitis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 40: If patients develop uveitis while on anti-TNF, a trial of an alternative anti-TNF agent could be considered. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendation 41: Anti-TNF should be used with caution in patients with a history of previous uveitis and the relative risks of the available anti-TNF agents should be reviewed prior to selecting which treatment to use. (&lt;strong&gt;Level III evidence, Grade of recommendation B&lt;/strong&gt;)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th width=&quot;4%&quot; valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Ia&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analysis of randomised controlled trials (RCTs)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Ib&lt;/th&gt;&#xD;&#xA;            &lt;td&gt;At least one RCT&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IIa&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one well-designed controlled study, but without randomisation&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IIb&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one well-designed quasi-experimental design&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;At least one non-experimental descriptive study (e.g., comparative, correlation, or case study)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;IV&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert committee reports, opinions, and/or experience of respected authorities&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Type of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analysis of randomised controlled trials (RCTs) &lt;em&gt;or&lt;/em&gt; at least one RCT&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Well-designed controlled study but without randomisation &lt;em&gt;or&lt;/em&gt; well-designed quasi-experimental study &lt;em&gt;or&lt;/em&gt; well-designed descriptive study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert committee reports, opinions, &lt;em&gt;and/or&lt;/em&gt; experience of respected authorities&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adalimumab. Chesterfield (UK): Arthritis Research UK; 2011. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Society for Rheumatology. Guidelines for vaccinations in the immunocompromised person. [internet]. London (England): British Society for Rheumatology; 2002&amp;nbsp;[accessed 2010 Jan 20]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Etanercept. Chesterfield (UK): Arthritis Research UK; 2011. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Infliximab. Chesterfield (UK): Arthritis Research UK; 2011. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The data supporting recommendations on safety aspects of anti-TNF therapy were derived primarily from observational studies, and to a lesser degree from evidence from randomised controlled trials (RCTs). Many of the studies might have addressed the general topic under discussion but did not specifically address the questions of relevance. Therefore, the recommendations could not be derived directly from the evidence but required synthesis of the data from studies plus extrapolation to the specific clinical scenarios under consideration. As a result, many of the recommendations were graded as Level C.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate and safe use of anti-tumour necrosis factor (anti-TNF) therapies in patients with rheumatoid arthritis (RA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adverse effects and complications associated with anti-tumour necrosis factor (anti-TNF) therapy&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Anti-tumour necrosis factor (anti-TNF) therapy should not be initiated in the presence of serious active infections. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anti-TNF therapy should not be given when there is a clear history of multiple sclerosis and should be used with caution with other demyelinating diseases. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines do not cover anti-TNF drugs that are still at an experimental stage of development.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;How Will These Guidelines Be Publicized and Implemented?&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The full guidelines will be published on the British Society for Rheumatology (BSR) Website, and sent to all BSR members and primary care trusts. A summary of the guidelines will be published in &lt;em&gt;Rheumatology&lt;/em&gt;, with web links to the full guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Safety" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C, Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee and BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. London (England): British Society for Rheumatology; 2010. 23 p.  [206 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837498&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2001 (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British Health Professionals in Rheumatology - Professional Association" /><FieldValue Value="British Society for Rheumatology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British Society for Rheumatology&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee and BHPR&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Working Group Members&lt;/em&gt;: Tina Ding, Rheumatology Department, Royal Derby Hospital, Derby; Jo Ledingham, Rheumatology Unit, Queen Alexandra Hospital, Portsmouth; Raashid Luqmani, Rheumatology Department, Nuffield Orthopaedic Centre, Oxford; Sarah Westlake, Rheumatology Department, Poole Hospital, Poole; Kimme Hyrich, ARC Epidemiology Unit, University of Manchester, Manchester; Mark Lunt, ARC Epidemiology Unit, University of Manchester, Manchester; Patrick Kiely, Rheumatology Department, St George's Healthcare, London; Marwan Bukhari, Rheumatology Department, Royal Lancaster Infirmary, Lancaster; Rikki Abernethy, Rheumatology Department, St Helens Hospital, St Helens; Ailsa Bosworth, National Rheumatoid Arthritis Society, Maidenhead; Andrew Ostor, Rheumatology Department, Addenbrooke's Hospital, Cambridge; Kate Gadsby, Rheumatology Department, Royal Derby Hospital, Derby; Frank McKenna, Rheumatology Department, Trafford General Hospital, Manchester; Diana Finney, Rheumatology Unit, Worthing and Southlands NHS Trust, Worthing; Josh Dixey, Rheumatology Department, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK; Chris Deighton, Rheumatology Department, Royal Derby Hospital, Derby&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Disclosure statement&lt;/em&gt;: J.L. has no personal conflicts of interest. Her department has received support from all the companies for educational meetings and specifically from Wyeth for its patient education programme and from Abbott for anti-cyclic citrullinated peptide (anti-CCP) testing for its patients and for the purchase of an ultrasound machine. A.B.'s organization has received educational grants from MSD (Schering-Plough), Abbott, Pfizer (Wyeth), and UCB. R.A. has previously sat on an advisory board for Roche and received honoraria for talks at symposia sponsored by Wyeth and Abbott. She has received personal support from Wyeth and Abbott to attend international educational meetings and the Department of Rheumatology at St Helens Hospital has received sponsorship from Wyeth, Abbott, Roche, Bristol-Myers Squibb, and Schering-Plough Pharmaceuticals for support of clinical meetings. M.B. has attended meetings organized by Schering-Plough and Wyeth, has been sponsored to attend international meetings by Pfizer, Merck, Roche, Wyeth, and Abbott, and has accepted honoraria for educational meetings from Merck, Wyeth, Abbott, Roche, UCB Celltech, Mennarini, and Pfizer. He has also departmental sponsorship for software from Wyeth, Abbott, and Roche. R.L. has received financial support from Wyeth, Roche, and Abbott to attend American College of Rheumatology (ACR) and European League Against Rheumatology (EULAR) meetings. S.W. has received an unconditional education grant from Abbott as part of the 3E project. A.O.&amp;nbsp;has received support from (including attendance at conferences), undertakes clinical trials and acts as a consultant to Roche, Chugai, Schering-Plough/MSD, Abbott, Wyeth, BMS, GSK, MerckSorono, and UCB. P.K has received departmental support for service and research from Sanofi-Aventis, Schering-Plough, and Wyeth and has received advisory fees, speaker fees, and unrestricted educational grants from Abbot, Bristol-Myers Squibb, Novartis, Roche, Schering-Plough, UCB, and Wyeth. K.G. sits on advisory boards for Schering-Plough, UCB, and Roche and has received honoraria for talks at symposia sponsored by Wyeth, Abbott, and Roche. C.D. has received honoraria for talks at symposia sponsored by Wyeth and Abbott. The Department of Rheumatology at Derbyshire Royal Infirmary has received sponsorship from Wyeth, Abbott, and Schering-Plough Pharmaceuticals for support of clinical meetings, and unrestricted grants to support an US machine, an anti-tumour necrosis factor (anti-TNF) audit clerk and research nurse. All other authors have declared no conflicts of interest.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF-&amp;alpha; blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44: 157-63.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://rheumatology.oxfordjournals.org/content/suppl/2010/09/14/keq249a.DC1/keq249b.pdf&quot; title=&quot;Rheumatology Journal Web site&quot;&gt;Rheumatology Journal Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P, Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F, Finney D, Dixey J, Deighton C; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Executive summary. Rheumatology (Oxford). 2010 Nov;49(11):2217-9. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://rheumatology.oxfordjournals.org/content/49/11/2217.full.pdf&quot; title=&quot;Rheumatology Journal Web site&quot;&gt;Rheumatology Journal Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on December 31, 2012. The information was verified by the guideline developer on February 8, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
